swethaann23 swethaann23
4 years ago
Minimal disease activity achievement in PsA achieved by 22.8% in 6 mo of b/ts DMARD
MDA achievers were:
➡️Younger
➡️🔽 Disease duration;
➡️ Male
➡️Non-obese
➡️bDMARD-naïve at baseline
➡️🔼 probability achieving MDA components➕MCID PROMs at 6 mo
Abst# 1344 #ACR21 @Rheumnow
Richard Conway RichardPAConway
4 years ago
Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM
sheila RHEUMarampa
4 years ago
In this study,
⭕AS pts w/>=2 #comorbidities were associated w/ poorer outcome measures after 2 yrs of ffup vs. pts w/ no comorbids
⭕Pts w/ >=2 comorbids were likely to dc 1st anti-TNF
Address comorbidities, ⬆ chances of better outcomes & QoL
@RheumNow #ACR21 abs1309 https://t.co/sTnjaC1a1l
Eric Dein ericdeinmd
4 years ago
#ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA
⭐️ECM biomarkers predict SDAI remission or DAS28 w ABA+MTX vs PBO+MTX.
⭐️⬆️CTX1 biomarker predicts efficacy endpts for ABA+MTX
https://t.co/7wHQefb5D4 @Rheumnow
Mrinalini Dey DrMiniDey
4 years ago
Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-naïve or inadequate responders to MTX and/or TNFi pts.
≥50% improvement in SJC/TJC at Wk 12 was assoc with wk 24/26 remission/low disease activity.
Abs#1237 #ACR21 @RheumNow https://t.co/PAaCe5MAcu
Eric Dein ericdeinmd
4 years ago
#ACR21 - Starting soon - The Gift of Gab! with @BayviewMedicine @jhrheumatology Jason Liebowitz moderating Communication for the Physician with @Wharton Janet Zeide. Learn about the RHEUM acronym for speaking! @Rheumnow https://t.co/wcgFUBcZeX
Dr. Antoni Chan synovialjoints
4 years ago
EULAR update on vaccines. HZ vaccine safe with csDMARDs and TNFα blockers. Reduced cell immune response after 1 year. Assess Varicella Abs if exposure unknown. Non-live recombinant subunit adjuvant zoster vaccine may be a game changer @RheumNow #ACR21 8M101 https://t.co/PTLqYGRIGf
TheDaoIndex KDAO2011
4 years ago
Innovative!
Self-home fetal heart rate monitoring by the mother is feasible, accurate, effective for those with +anti-Ro/SSA Ab.
The study is still recruiting https://t.co/9BFihsgW5A Abst#1464 #ACR21 @rheumnow
https://t.co/ggmOpSGdZk
Dr. John Cush RheumNow
4 years ago
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Mrinalini Dey DrMiniDey
4 years ago
Abs#1036: illness-related uncertainty significantly correlates with #depression, #anxiety, and sickness impact in patients with autoimmune #rheumaticdiseases.
Particularly strong associations with #AAV and #SSc.
#MentalHealth #ACR21 @RheumNow
https://t.co/SiV9fst3Bh https://t.co/w8VRQHdAJC
Aurelie Najm AurelieRheumo
4 years ago
⚡️A new biomarker of structural progression in RA? Plasma levels of CXCL13 ⬆️ @ baseline vs. ctrl and ⬇️ (p< 0.0001) after 1 yr treatment in a eRA cohort. Levels above 85pg/ml ⬆️ x5 risk of > severe radiographic status at 11yrs. @RheumNow #ACR21 #Abst1204 https://t.co/LnkayR1YrY https://t.co/W0xsgGuUDW
Eric Dein ericdeinmd
4 years ago
#ACR21 Abst#1204. CXCL13 predicts long-term radiographic status in early RA
▶️ early RA has ⬆️ CXCL13, and ⬇️ w treatment
⭐️CXCL13 was best predictor of long-term radiographic destruction - better than DAS28CRP and CRP
@Rheumnow https://t.co/ydYRbKMBZ2 https://t.co/qinEFb86Az
Robert B Chao, MD doctorRBC
4 years ago
Increased risk of vertebral fractures in PsA pts
OR 2.09 from meta-analysis and systematic review
Abs#1304
#ACR21
@RheumNow
https://t.co/0IazVBGHsF https://t.co/YrPMh1TZ6U
Eric Dein ericdeinmd
4 years ago
#ACR21 Abst#1229: Does BMI influence efficacy of SC (fixed dose) vs IV (body-wt adjusted) ABA in RA?
⭐️No difference between SC and IV ABA by BMI
⭐️BMI impacts response to ABA as >2nd line therapy and retention, but no difference bw dosing
https://t.co/LqfZvLhBzU @Rheumnow


Poster Hall